Fig. 2From: Development of a human phage display-derived anti-PD-1 scFv antibody: an attractive tool for immune checkpoint therapyBinding of soluble monoclonal scFvs to PD-1 and BSA-coated (negative control) wells. Data are presented as means [± SD] of OD values from triplicate experiments. An arbitrary cutoff three times greater than the negative control was considered positiveBack to article page